APO-ELETRIPTAN TABLETS 40 MG
ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) : 40 MG · DIN 02518023 · APOTEX INC
Health Canada status: MARKETED
What is APO-ELETRIPTAN TABLETS?
APO-ELETRIPTAN TABLETS 40 MG contains ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 02518023, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 01-Jun-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-ELETRIPTAN TABLETS used for?
Acute treatment of migraine with or without aura in adults. Not for prophylactic therapy or management of hemiplegic, ophthalmoplegic or basilar migraine.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02518023 |
|---|---|
| Brand name | APO-ELETRIPTAN TABLETS |
| Generic / active ingredient | ELETRIPTAN (ELETRIPTAN HYDROBROMIDE) : 40 MG |
| Manufacturer | APOTEX INC |
| Strength | 40 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N02CC06 ELETRIPTAN |
| AHFS class | 28:10.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Jun-2022 |
How is it administered?
Acute treatment of migraine. Not for prophylaxis. Not recommended for patients <18 or >65 years of age. Caution in mild/moderate renal impairment (max 20mg daily).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text (Table of Contents lists page 19, but text ends at page 11).
How is it supplied?
Not explicitly detailed in provided text (mentions 20 mg and 40 mg strengths).
Contraindications
Ischemic cardiac, cerebrovascular or peripheral vascular syndromes; uncontrolled/severe hypertension; severe hepatic impairment; use within 72h of potent CYP3A4 inhibitors; use within 24h of other 5-HT1 agonists/ergots.
Warnings and precautions
Risk of myocardial ischemia/infarction; cerebrovascular events; serotonin syndrome with SSRIs/SNRIs; medication overuse headache; potential for increased blood pressure; seizures.
Is ELETRIPTAN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N02CC06 ELETRIPTAN. 16 of 20 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-ELETRIPTAN TABLETS | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02518015 |
| AURO-ELETRIPTAN | 20 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02479451 |
| AURO-ELETRIPTAN | 40 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02479478 |
| ELETRIPTAN | 20 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02511266 |
| ELETRIPTAN | 40 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02511274 |
| JAMP ELETRIPTAN | 20 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02493683 |
| JAMP ELETRIPTAN | 40 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02493691 |
| MYLAN-ELETRIPTAN | 20 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02342235 |
| MYLAN-ELETRIPTAN | 40 MG | TABLET | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02342243 |
| PRO-ELETRIPTAN | 20 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02489961 |
Who else supplies ELETRIPTAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ELETRIPTAN appears in 54 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.